Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033137 · ClinicalTrials.gov registry record
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
A clinical trial of Kidney Cancer and Kidney Neoplasms, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 950
- Enrollment target
- 1
- Study location
NCT00033137: Recruiting study of Kidney Cancer and Kidney Neoplasms, sponsored by National Cancer Institute (NCI).
NCT00033137 is a study of Kidney Cancer and Kidney Neoplasms that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 950 participants, above the 865-participant average among 60 other Kidney Cancer trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033137, a study of Kidney Cancer and Kidney Neoplasms, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 950 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate the genetic cause of Birt Hogg-Dube (BHD) syndrome and the relationship of this disorder to kidney cancer. BHD is a rare inherited condition characterized by papules, or bumps-benign tumors involving hair follicles-on the head and neck. People with BHD are at increased risk of developing kidney cancer. Scientists have identified the chromosome (strand of genetic material in the cell nucleus) that contains the BHD gene and the region of the gene on the chromosome. This study will try to learn more about: * The characteristics and type of kidney tumors associated with BHD * The risk of kidney cancer in people with BHD * Whether more than one gene causes BHD * The genetic mutations (changes) responsible for BHD Patients with known or suspected Birt Hogg-Dube syndrome, and their family members, may be eligible for this study. Candidates will be screened with a family history and review of medical records, including pathology reports for tumors, and films of computed tomography (CT) and magnetic resonance imaging (MRI) scans. Participants may undergo various tests and procedures, including the following: * Physical examination * Review of personal and family history with a cancer doctor, cancer nurses, kidney surgeon, and genetic counselor * Chest and other x-rays * Ultrasound (imaging study using sound waves) * MRI (imaging study using radiowaves and a magnetic field) * CT scans of the chest and abdomen (imaging studies using radiation) * Blood tests for blood chemistries and genetic testing * Skin evaluation, including a skin biopsy (surgical removal of a small skin tissue sample for microscopic evaluation) * Cheek swab or mouthwash to collect cells for genetic analysis * Lung function studies * Medical photography of skin lesions These tests will be done on an outpatient basis in either one day or over 3 to 4 days. When the studies are complete, participants will receive counseling about the findings and recommendations. Patients with
Primary Outcome
Collection of blood, saliva, tissue \& urine for Identification of the Disease Gene, and Characterization of the disposition to Renal Cancer
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 950 participants |
| Start Date | 2002-05-13 |
What NCT00033137 shows while recruiting
NCT00033137 is an observational study that tracks outcomes without assigning an intervention. The registered 950 participants enrollment target is mid-sized for trials with a published cap, above the 865-participant average among 60 other Kidney Cancer trials with a reported enrollment target (10% higher).
The record links to 4 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00033137 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00033137 about?
NCT00033137 is a clinical study titled "Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer". This study will investigate the genetic cause of Birt Hogg-Dube (BHD) syndrome and the relationship of this disorder to kidney cancer. BHD is a rare inherited condition characterized by papules, or bumps-benign tumors involving hair follicles-on the head and neck. People with BHD are at increased ri...
What is the current status of trial NCT00033137?
This trial is currently recruiting. The enrollment target is 950 participants. The study started on 2002-05-13.
What conditions does trial NCT00033137 study?
This clinical trial studies the following conditions: Kidney Cancer, Kidney Neoplasms, Pneumothorax, FLCN Protein, Human.
Who is sponsoring clinical trial NCT00033137?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00033137 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00033137's enrollment target sits among peer trials
950 8th of 60 higher than 53 of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
RECRUITING · NA
-
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
RECRUITING
-
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
RECRUITING
-
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
RECRUITING
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT04375033 · 952 participants · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI